Mirtazapine Treatment of Social Phobia in Women: A Randomized, Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Social phobia is an anxiety disorder characterized by extreme fear and phobic avoidance of social and performance situations and by a relatively poor health-related quality of life. The goal of this study was to compare the efficacy of mirtazapine versus placebo in the treatment of patients with social phobia. In 2004, we conducted a randomized, double-blind, placebo-controlled study of mirtazapine in 66 female subjects from the general population meeting the criteria for social phobia. The subjects were randomly assigned in a 1:1 manner to mirtazapine (n = 33) or placebo (n = 33). The treatment lasted 10 weeks. Seven patients dropped out. Primary outcome measures were self-reported changes on the Social Phobia Inventory, Liebowitz Social Anxiety Scale, and Health Survey (SF-36). In comparison with the placebo group and according to the intent-to-treat principle, significant differences on the Social Phobia Inventory and Liebowitz Social Anxiety Scale scales (all P < 0.001), as well as on most (5 from 8) scales of SF-36 (all P < 0.001), were observed in the mirtazapine-treated subjects. All patients tolerated mirtazapine relatively well. Mirtazapine appears to be an effective agent in the treatment of social phobia in women and in the improvement of their health-related quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
FRESCO, D. M., COLES, M. E., HEIMBERG, R. G., LIEBOWITZ, M. R., HAMI, S., STEIN, M. B., & GOETZ, D. (2001) · Psychological Medicine · doi:10.1017/s0033291701004056 · Cited by 874 · cited 1×
“94.(20,21) The SF-36 Health Survey(22,23) was designed to obtain individual reports from patients on their health-related quality of life, independent of their current state of health and age.”
MethodPande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227
Research works printed but not linked: 16
- Antony, 1997, Can J Psychiatry, 42, 826, 10.1177/070674379704200804 · DOI · Paper page
- Kessler, 1994, Arch Gen Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
- Wttchen, 1999, Eur Psychiatry, 14, 118, 10.1016/S0924-9338(99)80729-9 · DOI · Paper page
- Tillfors, 2002, Biol Psychiatry, 52, 1113, 10.1016/S0006-3223(02)01396-3 · DOI · Paper page
- Liebowitz, 2003, J Clin Psychiatry, 64, 785, 10.4088/JCP.v64n0708 · DOI · Paper page
- Stein, 1999, Am J Psychiatry, 156, 756, 10.1176/ajp.156.5.756 · DOI · Paper page
- Goodnick, 1999, J Clin Psychiatry, 60, 446, 10.4088/JCP.v60n0705 · DOI · Paper page
- Van Veen, 2002, Int Clin Psychopharmacol, 17, 315, 10.1097/00004850-200211000-00008 · DOI · Paper page
- Liappas, 2003, J Affect Disord, 76, 279, 10.1016/S0165-0327(02)00094-0 · DOI
- Haapasalo-Pesu, 2004, J Child Adolesc Psychopharmacol, 14, 175, 10.1089/1044546041649110 · DOI
- Rickels, 2004, J Clin Psychopharmacol, 24, 488, 10.1097/01.jcp.0000138764.31106.60 · DOI · Paper page
- Kobak, 2005, J Clin Psychopharmacol, 25, 51, 10.1097/01.jcp.0000150227.61501.00 · DOI · Paper page
- Westenberg, 2004, J Clin Psychopharmacol, 24, 49, 10.1097/01.jcp.0000104906.75206.8b · DOI · Paper page
- Van Ameringen, 2004, J Clin Psychopharmacol, 24, 42, 10.1097/01.jcp.0000104909.75206.6f · DOI · Paper page
- Nickel, 2004, Wien Med Wochenschr, 154, 163, 10.1007/s10354-004-0058-z · doi:10.1007/s10354-004-0058-z
- Nickel, 2004, J Clin Psychiatry, 65, 1515, 10.4088/JCP.v65n1112 · DOI · Paper page
Cited by
Stein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Mirtazapine has demonstrated efficacy for the treatment of panic disorder in several open”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“The evidence for the efficacy of mirtazapine in patients with anxiety disorders is limited and inconsistent (Andrisano et al., 2013; Muehlbacher et al., 2005; Schutters et al., 2010), but in depressed patients treatment-emergent sexual dysfunction is probably less frequent than with SSRIs [I (M)] (Watanabe et al.”
ResultPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Metadata
- Authors
- Muehlbacher, M., Nickel, M. K., Nickel, C., Kettler, C., Lahmann, C., Gil, F. P., Leiberich, P. K., Rother, N., Bachler, E., Fartacek, R., Kaplan, P., Tritt, K., Mitterlehner, F., Anvar, J., Rother, W. K., Loew, T. H., & Egger, C.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2005-12
- Volume
- 25
- Issue
- 6
- Pages
- 580-583
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1974450862
- Cited by
- 79
- References
- 3
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mirtazapine Treatment of Social Phobia in Women: A Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1097/01.jcp.0000186871.04984.8d
- The paper
- Muehlbacher, M., Nickel, M. K., Nickel, C., Kettler, C., Lahmann, C., Gil, F. P., Leiberich, P. K., Rother, N., Bachler, E., Fartacek, R., Kaplan, P., Tritt, K., Mitterlehner, F., Anvar, J., Rother, W. K., Loew, T. H., & Egger, C. (2005). Mirtazapine Treatment of Social Phobia in Women: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000186871.04984.8d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.